Clinical trial
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia…
NCT00071006 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00071006 |
|---|---|
| Title | AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) |
| Official title | Phase 2 Study Of AG-013736 In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | AG-013736 (Axitinib) |
| Enrollment | 12 |
| Start date | Sep 1, 2003 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Oct 13, 2003 |
| Last update posted | Jun 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: